Atypical immunologic response in a patient with CRIM-negative Pompe disease

Molecular Genetics and Metabolism

Volumn 104, Issue 4, 2011, Pages 583-586

  Abbott, Mary Alice ^a   Prater, Sean N ^b   Banugaria, Suhrad G ^b   Richards, Susan M ^c   Young, Sarah P ^b   Rosenberg, Amy S ^d   Kishnani, Priya S ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GENZYME CORPORATION   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antibodies; Enzyme replacement therapies; Glycogen storage disease type II; Immunologic response; Pompe disease

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ARTIFICIAL VENTILATION; CARDIOMEGALY; CARDIOMYOPATHY; CASE REPORT; CHILD; CROSS REACTIVE IMMUNOLOGIC MATERIAL NEGATIVE; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FAMILY; FAMILY HISTORY; FATALITY; FEMALE; GASTROSTOMY; GLYCOGEN STORAGE DISEASE TYPE 2; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOMODULATION; INFLUENZA A; MOTOR DEVELOPMENT; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; SURVIVAL; TACHYCARDIA; THORAX RADIOGRAPHY; TRACHEOSTOMY;

ALPHA-GLUCOSIDASES; CROSS REACTIONS; ENZYME REPLACEMENT THERAPY; FATAL OUTCOME; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL DIAGNOSIS; RECOMBINANT PROTEINS; SEROLOGIC TESTS; TREATMENT FAILURE;

EID: 82255179514     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.08.003     Document Type: Article

References (20)

1. Hirschhorn R., Reuser A.J.J. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease 2009, McGraw-Hill, New York. D. Valle, C.R. Scriver (Eds.).
2. van den Hout H.M., Hop W., van Diggelen O.P., Smeitink J.A., Smit G.P., Poll-The B.T., Bakker H.D., Loonen M.C., de Klerk J.B., Reuser A.J., van der Ploeg A.T. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003, 112:332-340.
3. Kishnani P.S., Hwu W.L., Mandel H., Nicolino M., Yong F., Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006, 148:671-676.
4. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
5. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., Arnold G.L., Pivnick E.K., Ottinger C.J., Robinson P.H., Loo J.C., Smitka M., Jardine P., Tato L., Chabrol B., McCandless S., Kimura S., Mehta L., Bali D., Skrinar A., Morgan C., Rangachari L., Corzo D., Kishnani P.S. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
6. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., Bauer M.S., Jokic M., Tsai C.E., Tsai B.W., Morgan C., O'Meara T., Richards S., Tsao E.C., Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 2009, 66:329-335.
7. Kishnani P.S., Goldenberg P.C., DeArmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2010, 99:26-33.
8. Banugaria S.G., Prater S.N., Ng Y.K., Kobori J.A., Finkel R.S., Ladda R.L., Chen Y.T., Rosenberg A.S., Kishnani P.S. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet. Med. 2011, 13:729-736.
9. Rohrbach M., Klein A., Kohli-Wiesner A., Veraguth D., Scheer I., Balmer C., Lauener R., Baumgartner M.R. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J. Inherit. Metab. Dis. 2010, 33:751-757.
10. Young S.P., Zhang H., Corzo D., Thurberg B.L., Bali D., Kishnani P.S., Millington D.S. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet. Med. 2009, 11:536-541.
11. Hermans M.M., de Graaff E., Kroos M.A., Wisselaar H.A., Willemsen R., Oostra B.A., Reuser A.J. The conservative substitution Asp-645→Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem. J. 1993, 289(Pt 3):687-693.
12. Kishnani P.S., Nicolino M., Voit T., Rogers R.C., Tsai A.C., Waterson J., Herman G.E., Amalfitano A., Thurberg B.L., Richards S., Davison M., Corzo D., Chen Y.T. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 2006, 149:89-97.
13. Vogel M., Staller W., Buhlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children. Pediatr. Cardiol. 1991, 12:143-149.
14. McDowell R., Li J.S., Benjamin D.K., Morgan C., Becker A., Kishnani P.S., Kanter R.J. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet. Med. 2008, 10:758-762.
15. Sun B., Zhang H., Franco L.M., Young S.P., Schneider A., Bird A., Amalfitano A., Chen Y.T., Koeberl D.D. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 2005, 11:57-65.
16. Mendelsohn N.J., Messinger Y.H., Rosenberg A.S., Kishnani P.S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N. Engl. J. Med. 2009, 360:194-195.
17. Rohrbach M., Klein A., Kohli-Wiesner A., Veraguth D., Scheer I., Balmer C., Lauener R., Baumgartner M.R. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J. Inherit. Metab. Dis. 2010, 33:751-757.
18. Dickson P., Peinovich M., McEntee M., Lester T., Le S., Krieger A., Manuel H., Jabagat C., Passage M., Kakkis E.D. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J. Clin. Invest. 2008, 118:2868-2876.
19. Brooks D.A. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. 1999, 68:268-275.
20. Brooks D.A., Kakavanos R., Hopwood J.J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol. Med. 2003, 9:450-453.